KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.

Alessandro Armuzzi, David T Rubin, Stefan Schreiber, Julian Panés, Marc Fellmann, Lauren Bartolome, David Gruben, Martina Goetsch, Abhishek Bhattacharjee, María Chaparro, Marla C Dubinsky

Inflamm Bowel Dis 31(6) 1583-1594

PMID39326009
PMCIDPMC12166301
DOI10.1093/ibd/izae229
发表日期2024-09-26
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:非 KM 图;Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图。
摘要

摘要

BACKGROUND: Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Here, we evaluate the impact of etrasimod 2 mg QD on health-related quality of life (HRQoL) in patients with UC. METHODS: This post hoc analysis used data from the Phase 3 randomized controlled trials, ELEVATE UC 52 and ELEVATE UC 12. HRQoL measures included: Inflammatory Bowel Disease Questionnaire (IBDQ), 36-Item Short Form Survey (SF-36), and Work Productivity and Activity Impairment Questionnaire: Ulcerative Colitis (WPAI:UC) completed at baseline, Week 12 (both trials), and Week 52 (ELEVATE UC 52 only). For IBDQ analyses, patients were stratified by prior exposure to biologics/Janus kinase inhibitors (JAKi) and baseline modified Mayo score (MMS; 4-6 or 7-9). RESULTS: Generally, significantly greater proportions of patients receiving etrasimod (N = 527) vs placebo (N = 260) achieved IBDQ remission (IBDQ total score ≥170) and IBDQ response (IBDQ total score increase from baseline ≥16), with significant improvement in all IBDQ domain scores at Week 12 and maintained through Week 52. Significant differences in IBDQ remission and IBDQ response rates between etrasimod and placebo were more consistent among biologic/JAKi-naive patients vs those who were biologic/JAKi-experienced and in those with baseline MMS 7-9 vs 4-6. Significant improvements were observed in several SF-36 domain and summary scores and WPAI:UC domain scores at Week 12 and Week 52. CONCLUSIONS: Etrasimod 2 mg QD demonstrated significant and clinically meaningful improvements across multiple HRQoL measures, including WPAI, vs placebo. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT03945188; NCT03996369.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical Abstract无图注
非 KM Figure
Figure 1.Proportion of patients achieving (A) IBDQ remission (IBDQ ≥ 170) and (B) IBDQ response (IBDQ total score increase from baseline ≥16) at Week 12 and Week 52 in ELEVATE UC 52 and Week 12 in ELEVATE UC 12. Data labels present percentage value with n / N in brackets underneath. Difference from placebo is adjusted difference. 95% CI and 2-sided P -value are based on Cochran-Mantel-Haenszel method adjusting to reported randomization stratification of (1) naive-to-biologic or JAKi therapy at study entry, (2) baseline corticosteroid use, or (3) baseline disease activity (MMS 4-6 or 7-9). Abbreviations: Δ, difference from placebo; IBDQ, Inflammatory Bowel Disease Questionnaire; JAKi, Janus kinase inhibitor; MMS, modified Mayo score; n , number of patients; N , number of patients in the full analysis set; QD, once daily; UC, ulcerative colitis.
非 KM Figure
Figure 2.LSM change from baseline and LSM treatment differences in IBDQ domain scores at (A) Week 12 and Week 52 in ELEVATE UC 52 and (B) Week 12 in ELEVATE UC 12. Estimates are from a mixed-effect model with repeated measures (ELEVATE UC 52) and an analysis of covariance model (ELEVATE UC 12) for change from baseline with a covariate for baseline score, and factors for naive-to-biologic/JAKi therapy at study entry (Yes/No), baseline corticosteroid use (Yes/No), baseline disease activity (MMS 4-6 or 7-9), and treatment. Covariates for visit and treatment-by-visit interaction were also included in the mixed-effect model with repeated measures. Abbreviations: Δ, LSM difference between treatments; IBDQ, Inflammatory Bowel Disease Questionnaire; JAKi, Janus kinase inhibitor; LSM, least squares mean; MMS, modified Mayo score; QD, once daily; UC, ulcerative colitis.
非 KM Figure
Figure 3.Actual mean SF-36 domain scores and LSM changes from baseline in PCS and MCS scores and SF-6D health utility index at (A) Week 12 and Week 52 in ELEVATE UC 52 and (B) Week 12 in ELEVATE UC 12. The SF-36 consists of 36 questions measuring 8 health domains which are scored from 0 (worst possible) to 100 (best possible). PCS and MCS measures were calculated using norm-based scoring. The SF-6D health utility index comprises 7 out of the 8 SF-36 domains (scored from 0.0 [worst measured health state] to 1.0 [best measured health state]). Estimates for PCS, MCS, and SF-6D are from mixed-effect model with repeated measures (ELEVATE UC 52) and an analysis of covariance model (ELEVATE UC 12) for change from baseline with a covariate for baseline score, and factors for naive-to-biologic/JAKi therapy at study entry (Yes/No), baseline corticosteroid use (Yes/No), baseline disease activity (MMS 4-6 or 7-9), and treatment. Covariates for visit and treatment-by-visit interaction were also included in the mixed-effect model with repeated measures. Abbreviations: JAKi, Janus kinase inhibitor; QD, once daily; SF-36, 36-Item Short Form Survey; SF-6D, Short-Form Six-Dimension; LSM, least squares mean; MCS, mental component summary; MMS, modified Mayo score; PCS, physical component summary; UC, ulcerative colitis.
非 KM Figure
Figure 4.LSM changes from baseline and LSM treatment differences in WPAI:UC domain scores at (A) Week 12 and Week 52 in ELEVATE UC 52 and (B) Week 12 in ELEVATE UC 12. Bracketed data labels are n / N . The WPAI:UC consists of 6 questions about the effect of UC on 4 domains, each expressed as percentages (0%-100%) of impairment, with lower values indicating less impairment due to disease-specific health problems. Estimates are from a mixed-effect model with repeated measures (ELEVATE UC 52) and an analysis of covariance model (ELEVATE UC 12) with repeated measures model for change from baseline with a covariate for baseline score, and factors for naive-to-biologic/JAKi therapy at study entry (Yes/No), baseline corticosteroid use (Yes/No), baseline disease activity (MMS 4-6 or 7-9), and treatment. Covariates for visit and treatment-by-visit interaction were also included in the mixed-effect model with repeated measures. Abbreviations: Δ, LSM difference between treatments; LSM, least squares mean; n , number of patients; N , number of patients in the full analysis set; QD, once daily; WPAI:UC, Work Productivity and Activity Impairment Questionnaire: Ulcerative Colitis.
非 KM Figure